11月 2025
- 首頁
- Precision for Medicine
11月 2025Precision for Medicine的市場佔有率分析
100% sourced from leading minds on the front lines of research.
Precision for Medicine(包含公司地區)
查看更多網站流量與參與度資訊- precisionformedicine.com
Precision for Medicine截至 11月 2025 的總收入為 200M - 500M
Precision for Medicine 熱門網域產生的總收入
Precision for Medicine 熱門網域 3 年內的總收入
Precision for Medicine 熱門網域的總收入
Precision for Medicine的熱門網域總造訪量
了解Precision for Medicine市場觸達率與潛在市場影響力。
過去 3 個月的訪問總量
子公司細目
Precision for Medicine的熱門網域平均造訪時長
分析Precision for Medicine參與度指標。
過去 3 個月平均造訪時長
子公司細目
Precision for Medicine的熱門網域平均頁面瀏覽量
了解Precision for Medicine如何保持使用者的參與度、培養其興趣,並鼓勵他們採取下一步。
過去 3 個月平均頁面瀏覽量
子公司細目
想要取得更深入的流量洞見?
篩選超過 2,030 萬家線上企業。在流量激增、開始或停止使用技術或獲得正面評價時,發現新的潛在客戶。
新聞與訊號來自Precision for Medicine
透過 Similarweb 銷售訊號提醒,每當目標受眾出現新的機會或威脅時,你就會收到每日更新的已識別購買訊號。
新聞Nicholas Richardson left Precision For Medicine, Inc. as deputy director on Sep 14th '25.Precision for Medicine, a next-generation provider of drug research and development services, today announced that Dr Nicholas Richardson has left his position as deputy director at the US Food and Drug Administration (FDA) overseeing hematologic malignancies to join Precision for Medicine as vice president, clinical development.
9月 14, 2025閱讀更多
新聞Precision For Medicine, Inc. hired Nicholas Richardson as Vice President, Clinical Development on Sep 11th '25.BETHESDA, Md., Sept. 11, 2025 /PRNewswire/ - Precision for Medicine, a global leader in biomarker-driven clinical research and development, today announced that Nicholas Richardson, DO, MPH, has joined the company as Vice President, Clinical Development.
9月 11, 2025閱讀更多
新聞Precision For Medicine, Inc. hired Baig as President of Precision for Medicine's Clinical Solutions business on Jan 1st '23.Ms. Baig first joined Precision for Medicine as General Manager, Clinical Solutions in 2022 and has served as President of Precision for Medicine's Clinical Solutions business since January 2023.
5月 20, 2025閱讀更多
查看所有Precision for Medicine信號
讓銷售團隊專注於最有希望的機會。透過安排機會的優先順序,並在正確的時間參與,您可將工作最佳化,並完成更多交易。